De novo lipogenesis during controlled overfeeding with sucrose or glucose in lean and obese women.
BACKGROUND
The results of previous studies suggest that de novo lipogenesis may play an important role in the etiology of obesity, particularly during overconsumption of different carbohydrates.


OBJECTIVE
We hypothesized that de novo lipogenesis would increase during overfeeding, would vary depending on the type of carbohydrate consumed, and would be greater in obese than in lean women.


METHODS
De novo lipogenesis was measured during 96 h of overfeeding by 50% with either sucrose or glucose and during an energy balance treatment (control) in 8 lean and 5 obese women. De novo lipogenesis was determined by measuring the amount of deuterium incorporation into plasma triacylglycerols. Fat and carbohydrate balance were measured simultaneously by continuous whole-body calorimetry.


RESULTS
De novo lipogenesis did not differ significantly between lean and obese subjects, except with the control treatment, for which de novo lipogenesis was greater in the obese subjects. De novo lipogenesis was 2- to 3-fold higher after overfeeding by 50% than after the control treatment in all subjects. The type of carbohydrate overfeeding (sucrose or glucose) had no significant effect on de novo lipogenesis in either subject group. Estimated amounts of absolute VLDL production ranged from a minimum of 2 g/d (control) to a maximum of 10 g/d after overfeeding. This compares with a mean fat balance of approximately 275 g after 96 h of overfeeding. Individual subjects showed characteristic amounts of de novo lipogenesis, suggesting constitutive (possibly genetic) differences.


CONCLUSIONS
De novo lipogenesis increases after overfeeding with glucose and sucrose to the same extent in lean and obese women but does not contribute greatly to total fat balance.
McDevitt
R M
RM
Department of Biochemistry and Nutrition, Scottish Agricultural College, Ayr, United Kingdom. r.mcdevitt@au.sac.ac.uk
Bott
S J
SJ
Harding
M
M
Coward
W A
WA
Bluck
L J
LJ
Prentice
A M
AM
D001823:Body Composition; D002153:Calorimetry, Indirect; D003903:Deuterium; D004040:Dietary Carbohydrates / Q000008:administration & dosage / Q000378:metabolism; D004041:Dietary Fats / Q000008:administration & dosage / Q000378:metabolism; D002149:Energy Intake; D004734:Energy Metabolism / Q000502:physiology*; D005260:Female; D005947:Glucose / Q000008:administration & dosage* / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000096:biosynthesis* / Q000493:pharmacokinetics; D008875:Middle Aged; D009765:Obesity / Q000209:etiology* / Q000378:metabolism; D012044:Regression Analysis; D013395:Sucrose / Q000008:administration & dosage* / Q000378:metabolism; D014280:Triglycerides / Q000096:biosynthesis / Q000493:pharmacokinetics
D004040:Dietary Carbohydrates; D004041:Dietary Fats; D008055:Lipids; D014280:Triglycerides; D013395:Sucrose; D003903:Deuterium; D005947:Glucose